Australia markets closed

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.9300+0.3400 (+13.13%)
At close: 04:00PM EDT
2.8600 -0.07 (-2.39%)
After hours: 07:35PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 8.60M
Enterprise value 3.56M
Trailing P/E 1.47
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.40
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.83

Trading information

Stock price history

Beta (5Y monthly) -0.15
52-week change 3-94.73%
S&P500 52-week change 322.36%
52-week high 367.7160
52-week low 31.9800
50-day moving average 33.6505
200-day moving average 320.5153

Share statistics

Avg vol (3-month) 349.66k
Avg vol (10-day) 315.84k
Shares outstanding 52.9M
Implied shares outstanding 62.95M
Float 82.63M
% held by insiders 14.08%
% held by institutions 18.59%
Shares short (15 Apr 2024) 48.47k
Short ratio (15 Apr 2024) 40.15
Short % of float (15 Apr 2024) 40.30%
Short % of shares outstanding (15 Apr 2024) 40.29%
Shares short (prior month 15 Mar 2024) 410.52k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:9
Last split date 314 Nov 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-34.72%
Return on equity (ttm)-37.08%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -4.88M
Net income avi to common (ttm)-2.16M
Diluted EPS (ttm)-3.6000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.45M
Total cash per share (mrq)1.19
Total debt (mrq)11.51k
Total debt/equity (mrq)0.25%
Current ratio (mrq)13.80
Book value per share (mrq)2.32

Cash flow statement

Operating cash flow (ttm)-6.58M
Levered free cash flow (ttm)-4.2M